Selectivity is key when meeting gold standards of future prostate cancer care. Diaprost´s monoclonal antibody platform will provide the best option for diagnosing and treating prostate cancer.
ANTIBODY PLATFORM FOR SPECIFIC DETECTION AND TREATMENT
The Diaprost pipeline is focused on humanized antibodies for both diagnostics and therapeutics targeting prostate specific antigens. Current focus is Prostate Specific Antigen (PSA), an antigen known to be abundant in prostate tissue and well-established for in vitro tests for PSA levels for identifying risk of prostate cancer.
The h5A10 project enables therapy of prostatic cancer through radioimmunotherapy and detection of prostate metastases by PET in combination with anatomical imaging (CT/MR), as well as intra-operative imaging.